TCT 342: Early Multi-center Clinical Outcomes of a No-Implant Interatrial Shunt for Heart Failure with Preserved and Reduced Ejection Fraction: Latest Results From the Early Feasibility ALLEVIATE-HF Programs
We Recommend
Disclosures
Within the last 24 months, I have financial relationship(s) or affiliation(s) with a manufacturer, marketer, reseller, or distributor of a healthcare product or service involved in the management of patients with any cardiovascular disease to include devices, drugs, and digital health care products listed below:
- Grant Support/Research Contract (Institutional) - Abbott Vascular; AstraZenca; Bayer AG; Bristol-Myers Squibb; CSL Behring; Daiichi-Sankyo/Elil Lilly and Company; Medtronic; OrbusNeich; Abiomed; Boston Scientific Corporation; Alleviant; Amgen; AM-Pharma; Applied Therapeutics; Arena; BAIM; Biosensors; Biotronik; CardiaWave; CellAegis; Concept Medical; CeloNova; CERC; Chiesi; Cytosorbents; Duke University; Element Science; Faraday; Humacyte; Idorsia; Insel Gruppe AG; Philips; RenalPro; Vivasure; Zoll
- Consultant Fee/Honoraria/Speaker's Bureau (Institutional) - Novartis Pharmaceuticals; Abbott Vascular; Janssen; Medtronic
- Equity/Stock(s)/Options (Personal) - Control Rad (spouse)
- Consultant Fee/Honoraria/Speaker's Bureau (Personal) - Medscape/WebMD; Cine-Med Research
- Scientific Advisory Board (Personal) - SCAI; AMA
- Equity
- BOT Member (Personal) - ACC